IP Library Granted Patent US 10,548,926
Granted Patent B2
US 10,548,926 · App. 15/068,123 · Granted Feb 4, 2020

Methods for collecting and using placenta cord blood stem cells

Inventor: Naoko Takebe (Elkridge, MD)
Assignee: CELULARITY, INC.
A61K35/51A61L27/3834C12N5/0605C12N5/0647A61K2035/124
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,548,926
App. No.
15/068,123
Granted
Feb 4, 2020
Kind
B2
Abstract

An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.

Claims (47)

1. A method for treating a mammal in need of hematopoietic reconstitution, the method comprising:

a) providing isolated stem cells by:

i) performing machine perfusion of an isolated mammalian placenta comprising cord blood comprising cord blood stem cells,

said performing machine perfusion being done with a pressure mediated pulsatile flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells,

wherein said isolated mammalian placenta is non-exsanguinated;

ii) collecting the perfusate; and

iii) isolating the cord blood stem cells from the perfusate to produce isolated cord blood stem cells; and

b) introducing into the bone marrow or peripheral blood of the mammal a composition comprising a therapeutically effective amount of cells selected from the group consisting of the isolated stem cells or hematopoietic cells derived therefrom.

2. The method according to claim 1 , wherein said introducing comprises:

introducing into the mammal a composition comprising a therapeutically effective amount of the isolated stem cells.

3. The method according to claim 1 , wherein said introducing comprises:

obtaining said cells derived therefrom by culturing in vitro the isolated stem cells, thereby producing said cells derived therefrom; and

introducing into the mammal a composition comprising a therapeutically effective amount of said cells derived therefrom.

4. The method according to claim 3 , wherein said cells derived therefrom are differentiated cells or expanded stem cells.

5. The method according to claim 1 , wherein said isolated stem cells comprise hematopoietic stem cells.

6. The method according to claim 5 , wherein the mammal in need of hematopoietic reconstitution has aplastic anemia, a hematopoietic malignancy, an autoimmune disease, a genetic disorder, an immunodeficiency, a malignant solid tumor, or a combination thereof.

7. The method according to claim 6 , in which the mammal in need of hematopoietic reconstitution has a hematopoietic malignancy selected from leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome.

8. The method according to claim 6 , in which the mammal in need of hematopoietic reconstitution has an immunodeficiency resulting from irradiation, chemotherapy, infection by a pathogenic microorganism, or a combination thereof.

9. The method according to claim 5 , wherein said introducing comprises introducing into the mammal intravenously or intraosseously a composition comprising a therapeutically effective amount of cells selected from the group consisting of the isolated stem cells and cells derived therefrom.

10. A method for treating a mammal in need of hematopoietic reconstitution, the method comprising:

a) isolating cord blood stem cells being by:

i) performing machine perfusion of an isolated mammalian placenta comprising cord blood comprising cord blood stem cells,

said performing machine perfusion being done with a pressure mediated pulsatile flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells,

wherein said isolated mammalian placenta is non-exsanguinated;

ii) collecting the perfusate; and

iii) isolating the cord blood stem cells from the perfusate to produce isolated cord blood stem cells;

b) optionally culturing in vitro isolated cord blood stem cells, thereby producing differentiated hematopoietic cells or expanded stem cells; and

c) introducing into the bone marrow or peripheral blood of the mammal a composition comprising a therapeutically effective amount of cells selected from the group consisting of:

i) said isolated cord blood stem cells;

ii) said differentiated hematopoietic cells or expanded stem cells, and

iii) combinations thereof;

whereby hematopoietic reconstitution is effected.

11. A method for treating a mammal in need of hematopoietic reconstitution, the method comprising:

a) providing isolated stem cells by:

i) providing an isolated mammalian placenta comprising cord blood comprising cord blood stem cells, wherein said isolated mammalian placenta is partially exsanguinated to produce a volume of cord blood comprising a first population of isolated cord blood stem cells;

ii) conducting machine perfusion of the isolated mammalian placenta with a pressure mediated flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells, wherein said machine perfusion is performed using a pump;

iii) collecting the perfusate; and

iv) isolating the cord blood stem cells from the perfusate to produce a second population of isolated cord blood stem cells;

wherein said second population of isolated cord blood cells has a greater percentage of CD133+ cells than said first population of isolated cord blood cells; and

b) introducing into the bone marrow or peripheral blood of the mammal a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells or hematopoietic cells derived from the second population of isolated cord blood stem cells.

12. The method according to claim 11 , wherein said introducing comprises:

introducing into the mammal a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells.

13. The method according to claim 11 , wherein said introducing comprises:

obtaining said cells derived therefrom by culturing in vitro cells from the second population of isolated cord blood stem cells, thereby producing said cells derived from the second population of isolated cord blood stem cells; and

introducing into the mammal a composition comprising a therapeutically effective amount of said cells derived from the second population of isolated cord blood stem cells.

14. The method according to claim 11 , wherein said introducing comprises introducing into the mammal a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells,

said composition further comprising cells from the first population of isolated cord blood stem cells.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2017
From: CELULARITY BIOSOURCING, LLC
To: CELULARITY, INC.
Reel/Frame 044098/0717 →
CHANGE OF NAME Recorded Nov 9, 2017
From: HLI CELLULAR THERAPEUTICS, LLC
To: CELULARITY BIOSOURCING, LLC
Reel/Frame 044707/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2016
From: TAKEBE, NAOKO
To: CORD BLOOD SCIENCE INC.
Reel/Frame 039942/0698 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2016
From: CORD BLOOD SCIENCE LLC
To: ANTHROGENESIS CORPORATION
Reel/Frame 039614/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2016
From: ANTHROGENESIS CORPORATION, A NEW JERSEY CORPORATION, D/B/A CELGENE CELLULAR THERAPEUTICS
To: HLI CELLULAR THERAPEUTICS, LLC, A DELAWARE LIMITED LIABILITY COMPANY
Reel/Frame 039615/0126 →